Long-term sequelae due to extravasation of intravenous radioisotopes resulting in radiation injuries are rarely reported. As the use of radioactive isotopes for the treatment of osteoblastic metastases increases, information regarding the prevention, treatment, and long-term monitoring of suspected extravasation injury will become increasingly important. We present a patient with no previous history of skin cancer who developed an aggressive cutaneous squamous cell carcinoma at the site of prior radium-223 extravasation. We recommend that patients who experience extravasation of therapeutic radioisotopes be monitored by dermatologists for long-term sequelae. Cutaneous squamous cell carcinoma should be recognized as a rare but potential adverse event following cutaneous extravasation of radium-223 and is likely a side effect that is severely underreported.
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I
ntravenous radium-223 improves survival and alleviates pain secondary to osteoblastic metastases in the setting of castration-resistant prostate cancer ( 1 ) . Surprisingly, there are very few reports of local adverse eff ects related to extravasation of radiotherapies at the injection sites. Ionizing radiation is a wellestablished risk factor in the formation of cutaneous squamous cell carcinoma. Lichter et al discovered that the risk of cutaneous squamous cell carcinoma was increased by an odds ratio of 2.94 in patients with sun-sensitive phenotypes who received ionized radiotherapy ( 2 ) . Although radium-223 has only been approved by the US Food and Drug Administration since 2013, we report a case of focal cutaneous squamous cell carcinoma that quickly developed after extravasation of radium-223. To our knowledge, this is the fi rst published case of this possible side eff ect.
CASE DESCRIPTION
A 62-year-old man presented with a painful, hyperkeratotic papule on the left dorsal hand. He had no prior history of skin cancer but did have a history of metastatic prostate cancer with an extensive oncological therapy course, including treatment with intravenous radium-223 dichloride injections at an outside facility for painful osteoblastic metastases. During the fi rst of three treatments (Figure 1 ) , he noted extravasation of the radioisotope from the intravenous catheter in his left dorsal hand, which manifested as local pain, erythema, and edema. Th e patient denied any postincident correlate imaging procedures or survey meter assessment to Focal cutaneous squamous cell carcinoma following radium-223 extravasation Katie E. Benjegerdes , BS, Shannon C. Brown , MD, and Chad D. Housewright, MD verify the presence of radioactivity at the site. Four months later, he noted a rapidly growing, painful lesion at the exact injection site. Upon examination, there was a 1.2 cm hyperkeratotic plaque, which was not present at his last skin check 5 months earlier (Figure 2 ) . Th ere was no signifi cant actinic damage or previous history of actinic keratosis in the area. A biopsy revealed an aggressive acantholytic squamous cell carcinoma. Th e patient then underwent Mohs micrographic surgery for defi nitive treatment.
DISCUSSION
Radium-223 dichloride is an alpha emitter that selectively targets and binds areas of increased metabolic activity and is approved for the treatment of pain secondary to osteoblastic metastases in the setting of castration-resistant prostate cancer. Th e ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer patients) trial was a phase 3 randomized double-blind trial that studied the eff ects and safety profi le of radium-223. Common adverse events analyzed in the study included myelosuppression, gastrointestinal disturbance, fatigue, urinary tract infections, pathologic fracture, and progression of malignant neoplasms ( 1, 3 ) . No cutaneous adverse eff ects were noted during the trial, and specifi cally there was no mention of local reactions at the injection site ( 3 ). Local radiation injuries due to extravasation of intravenous radiotherapies are rarely reported ( 4, 5 ) . Two cases of extravasation have been reported secondary to strontium-89 and yttrium-90-ibritumomab, a radiolabeled monoclonal antibody ( 4, 5 ) . In each of these cases, the patients experienced an immediate burning pain sensation, erythema, and edema. However, there was no mention of resulting skin cancers. Another important distinction is that both of these cases involved beta-minus-emitting radiotherapeutics instead of alpha-emitting radiotherapeutics and presumably at much higher doses than our patient received.
Proc (Bayl Univ Med
Th e fi rst report of radium directly causing a skin injury was in 1900 by Germans Friedrich Walkhoff and Friedrich Giesel ( 6 ). Dr. George H. Stover was one of the fi rst Americans to experiment with the eff ects of self-exposure to radium, which resulted in numerous skin cancers. By the time he passed away from radiation toxicity in 1915 at the age of 44, he had received over 150 skin grafts and lost two fi ngers to skin cancers ( 7, 8 ) . However, this was likely radium-226, which has a half-life of 1600 years, whereas radium-223 has a half-life of 11.4 days.
Modern reports involving cutaneous injuries secondary to radium are very rare. Wright et al analyzed the safety of radium-223 in regards to systemic circulation and extravasation into the soft tissues at the injection site ( 9 ) . Th e authors concluded that there were no cases of extravasation into the surrounding soft tissue. However, their study was limited by a small sample size of eight patients. Management guidelines for suspected extravasation of therapeutic radionuclides are present in many safety manuals ( 4, 7 ). Williams et al have discussed the importance of, and reasonable approach to, prevention and early treatment of suspected extravasation injury ( 5 ) . Th e proposed prevention measures include insertion and removal of the intravenous catheter by experienced personnel and the use of large veins between the wrist and antecubital fossa but obtaining access as distally as possible ( 5 ). Wright et al summarized an imaging-based methodology specifi c for extravasated intravenous radium-223 that would assist in detecting and quantifying the amount of radium in surrounding tissue ( 9 ) . Kawabe et al discussed safety guidelines for extravasation of strontium, which included four steps: documenting the site with a photograph, warming the region to promote vasodilation and alleviate pain, considering topical or intralesional steroids, and imaging the area to measure the dose of radiation absorbed by the skin ( 4 ). Th ey also recommended consulting a dermatologist to treat the associated symptoms. Iddins et al recommended considering hyperbaric oxygen or 400 mg of pentoxifylline and α-tocopherol (a form of vitamin E) for the treatment of local radiation injury ( 10 ) .
Th e true incidence of adverse eff ects due to the extravasation of radioisotopes is likely underreported. Physicians involved in the care of these patients may not be aware that extravasation occurred. Furthermore, skin cancers are very common on the dorsal hands and forearms, where intravenous catheters are commonly placed. Due to the prolonged and protracted nature of radiation-induced injuries and the delayed development of cutaneous complications such as nonmelanoma skin cancer, the physicians and patients may not connect the two events. We recommend that patients who experience extravasation of radiotherapies be monitored by a dermatologist for the development of possible aggressive skin cancers. Th ese measures in prevention, prompt detection, and treatment can decrease morbidity associated with extravasation of intravenous radiopharmaceuticals such as radium-223. 
